RPHM Gunggung Aset Perusahaan Reneo Pharma

Simbol resmi perusahaan Reneo Pharmaceuticals Inc. (RPHM)

This market valuation chart for Reneo Pharmaceuticals (RPHM) on the GURU.Markets platform demonstrates total assets, which currently stand at 113.37. The business generates revenue by bringing treatments for mitochondrial pathologies and muscle dysfunctions to market. Despite a reduction in the number of scientists following restructuring, stable demand for orphan drugs renders the firm's development independent of economic cycles and inflationary processes.

Reneo Pharma - Total Aset Perusahaan RPHM (periode 04.07.2022 - 07.10.2024)

Rincian metrik keuangan lan pasar Reneo Pharma (RPHM)

- rega lan prakiraan konsensus rega:
Kutipan saham reneopharma.com|RPHM - Bagan rega target
- data kapitalisasi pasar:
Kapitalisasi pasar Reneo Pharmaceuticals, Inc|RPHM - Nilai Total Perusahaan
- data nilai buku modal saham:
Nilai Buku Saham Reneo Pharmaceuticals|RPHM - Kapitalisasi Buku|Koefisien Nilai Pasar marang Nilai Buku reneopharma.com|RPHM - Total Aset Perusahaan
- rincian utang lan likuiditas:
Rasio Total Utang marang Ekuitas Reneo Pharmaceuticals|RPHM - Utang jangka dawa marang modal|Koefisien utang jangka cendhak marang modal Reneo Pharmaceuticals, Inc|RPHM - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Reneo Pharmaceuticals, Inc|RPHM - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Reneo Pharmaceuticals|Koefisien jangkoan perantara reneopharma.com
- rincian asil keuangan lan kelipatan valuasi:
RPHM - Penghasilan resik
Pambiji fundamental:Reneo Pharmaceuticals
Barang utama Reneo Pharmaceuticals

To build a high-quality portfolio, I utilize total assets (equity + liabilities), reverse-engineered via ROA to assess the actual scale of the business, which allows for the elimination of market illusions through the analysis of aggregate resources; in the case of Reneo Pharmaceuticals (RPHM), this indicator reflects the value of the proprietary patent base amid post-trial restructuring, transforming the dynamics of assets (equity + liabilities) into a survival marker for the biotech firm.

Pesaing utama

Gunggung Aset Perusahaan vrtx.com|Aset Agregat Perusahaan Alnylam|Insmed Inc. (INSM) - Gunggung Aset Perusahaan|Aset Agregat Perusahaan United Therapeutics Corp. (UTHR)|BMRN: Nilai Total Aset Perusahaan|Total Aset Perusahaan BBIO (BridgeBio Pharma, Inc.)|BGM Group Limited (BGM) - Aset Perusahaan|Cogent Biosciences, Inc. - Total Aset Perusahaan|Xeris Biopharma Holdings, Inc. (XERS) - Gunggung Aset Perusahaan|KROS: Total Aset Perusahaan|ARCT - Gunggung Aset Perusahaan|ETON (Eton Pharmaceuticals) - Total Aset Perusahaan|Total Aset Perusahaan kamada.com|Aset Agregat Perusahaan Fulcrum Therapeutics, Inc. (FULC)|Aset Agregat Perusahaan ABEO (abeonatherapeutics.com)|Total Aset Perusahaan MREO (Mereo BioPharma Group plc)|Gunggung Aset Perusahaan Protalix BioTherapeutics, Inc (PLX)|PLRX: Gunggung Aset Perusahaan|Nilai Total Aset Perusahaan APLT|RNTX: Total Aset Perusahaan|Aset Perusahaan Gelteq (GELS)|AYTU (Aytu BioPharma Inc) - Total Aset Perusahaan|Total Aset Bisnis CMMB (Chemomab)|Gunggung Aset Perusahaan SRXH (SRx Health Solutions Inc.)|PLRZ (polyrizon-biotech.com) - Nilai Agregat Aset|Aset Agregat Perusahaan Aeterna Zentaris Inc. AEZS|CYTH (Cyclo Therapeutics Inc.) - Nilai Total Aset Perusahaan|Inozyme - Total Aset Perusahaan|Nilai Agregat Aset CSCI (COSCIENS Bio)